Could a Low-Dose immune booster tame ALS?
NCT ID NCT02059759
First seen Nov 17, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tested whether a low dose of interleukin-2 (IL-2), a protein that helps regulate the immune system, is safe and can increase regulatory T cells in people with amyotrophic lateral sclerosis (ALS). 36 adults with ALS received either IL-2 or a placebo for five days. The main goal was to see if IL-2 could boost protective immune cells without causing serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.